Always nice to hear from you Mayo. There are a lot of us who just want the truth. Many of us have lost family and friends to dementia. We know the heavy burden of "the beholders disease" on entire families. Anavex is like a beacon light in the darkness. And the way it benefits such diverse problems as Alzheimers, PD, Rett, Fragile X etc. etc. speaks of a MOA that is truly unique! Thanks!
What are your thoughts regarding Dr. Timo Grimmer's comments regarding Anavex's Blarcamesine for the treatment of Alzheimer's disease on the Roche podcast. It is interesting that Roche is #5 on the top 5 pharmaceutical companies in the world.
Roche and Dr. Timo Grimmer, Investigator in the Anavex Blarcamesine Phase 2b/3 trial for the treatment of early stage Alzheimer's disease, newest member of the Anavix SAB (Scientific Advisory Board)
Notice that Roche is giving Dr. Grimmer an opportunity to tell his observations from the CTAD Congress.
Dr. Timo Grimmer über die Highlights des CTAD (Clinical Trials on Alzheimer's Disease) Kongresses.
Dr. Grimmer. “There is such a significant unmet medical need around the globe caused by Alzheimer’s disease and patients in the Phase 2b/3 ANAVEX®2-73-AD-004 study performed better even after a year despite the progression of this devastating disease. It would be groundbreaking for patients and their loved ones if healthcare professionals are able to provide a therapeutic which can be taken orally and is generally safe, which the study indicates, ANAVEX®2-73 (blarcamesine) is a likely candidate.”
Market Data 
Markets 
AI
